Our product pipeline is a combination of licensed research pharmaceuticals, recombitant vaccines and immunomodulators, hormones, and generics. While our recent diversification into biotechnology has added a new dimension to our company and our emphasis on commercialization of newly developed therapies continues to be our core area of focus, our generic formulations fuel business activity in developing markets earning us valuable goodwill, patronage and enabling closer interaction with patients and physicians, taking us a step closer to our vision of personalizing medicine.